Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...
Agence France-Presse

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...
Targeted Oncology

NDA for Rusfertide Submitted to FDA for Polycythemia Vera

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...